Details of the Drug Reposition

General Information of This Drug (ID: DM4Z9QI)

Drug Name
Olokizumab   DM4Z9QI
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rheumatoid arthritis DISTSB4J FA20 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2/3 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02760407) Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 2). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04380519) Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). U.S. National Institutes of Health.